A weekly shot form of Leqembi, given as two consecutive injections, could simplify use of the groundbreaking Alzheimer's treatment, potentially allowing patients to receive the drug at home instead of traveling to an infusion center twice a month. The Japanese drugmaker's review compared data for 72 patients with early Alzheimer's given Leqembi by subcutaneous injection to prior pivotal trial results from 898 patients who received the drug by infusion.
Shares of Eisai Co., Ltd. (OTCMKTS:ESALY – Get Free Report) passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $61.51 and traded as low as $61.00. Eisai shares last traded at $61.51, with a volume of 331,800 shares changing hands. Eisai Stock Performance […]
Japan's Health Ministry has approved Leqembi, a drug for Alzheimer's disease that was jointly developed by Japanese and US pharmaceutical companies. As the AP reports,.
Tokyo: Eisai Co., Ltd. and Biogen Inc. have announced that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody LEQEMBI Intravenous Infusion (200 mg, 500mg, lecanemab) has been.